DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Stifel Nicolaus Initiates Coverage On CRISPR Therapeutics with Hold Rating, Announces $52 Price Target

Stifel Nicolaus analyst Ben Burnett initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Hold rating and a $52 price target.

Benzinga · 03/05/2020 09:54

Stifel Nicolaus analyst Ben Burnett initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Hold rating and a $52 price target.